|
Oct 4
|
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
|
|
Jul 25
|
IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024
|
|
Jan 15
|
IO Biotech, Inc. (NASDAQ:IOBT) most popular amongst private equity firms who own 61% of the shares, institutions hold 24%
|
|
Dec 21
|
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
|
|
Dec 19
|
We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate
|
|
Oct 23
|
Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European S...
|
|
Aug 8
|
IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
|
|
Aug 7
|
IO Biotech, Inc. Announces $75 Million Private Placement Financing
|